Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline ...

A 41-year-old man was evaluated for swelling in the ankles and syncope. CT of the chest showed bilateral mediastinal and ...

Sarcoidosis is a systemic inflammatory disorder of unknown etiology, characterized by the formation of noncaseating granulomas, multisystem involvement, intrathoracic (pulmonary and lymph node ...

Among those treated for sarcoidosis in the year following diagnosis, 60% used steroids alone, 13% nonsteroidal immunosuppressives alone, and 27% received both. About 43% of patients with sarcoidosis ...

As devastating wildfires and smoke sweep across California, the Foundation for Sarcoidosis Research (FSR) urges individuals to prioritize their immediate and long-term health ...

Background A major gap in the management of sarcoidosis is the lack of accessible and objective methods to measure disease activity. Since 90% of patients have pulmonary involvement, we explored if a ...

or any of the cancers most prevalent among US veterans (melanoma or lung, prostate, colorectal, or bladder cancer). We found that adjusted all-cause [sarcoidosis] mortality is rising, with higher risk ...

Cardiology Unit of the Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York Pulmonary Disease Unit of the Department of Medicine, University of ...